Original articleNonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: analysis of intraoperative liver biopsies and literature review
Section snippets
Methods
We analyzed a large series of patients undergoing bariatric surgery at the Class III Obesity Center within a General Hospital (Public Health System) from 2001 to 2016. Data were obtained through a retrospective review of their medical records.
Patients were selected for bariatric surgery according to the criteria of the National Institutes of Health Consensus Statement [17]: body mass index (BMI) ≥40 kg/m² or ≥35 kg/m² associated with one or more co-morbidities, age between 18 and 65 years, and
Demographic and clinical characteristics
Of the 521 patients, 439 (84.3%) were women with a mean age of 41.8 ± 10 years. Patients were classified into 3 groups according to their baseline glucose status, as follows: group 1 (G1) composed of 167 (32.05%) type 2 diabetics, group 2 (G2) with 132 (25.33%) prediabetics, and group 3 (G3) containing 222 (42.61%) normoglycemic obese patients. The mean BMI of our patients was 51.87 kg/m². None of the patients had a BMI<40 kg/m². Clinical and demographic characteristics of patients are shown in
Discussion
This is one of the largest series of patients to correlate the glucose status of patients undergoing bariatric surgery with the degree of histologic liver damage. Additionally, to the best of our knowledge, we are the first to include a group of prediabetic patients in the analysis.
Using liver biopsies, we were able to establish the diagnosis of NASH, which is not accurately identified in most studies based on clinical criteria. NASH is a severe and progressive liver disease that can result in
Conclusion
We demonstrated that the degree of histologic liver damage is related to the presence of T2D in morbidly obese patients. Our data suggest that intraoperative liver biopsy should be considered for diabetic patients undergoing bariatric surgery. Early bariatric surgery should be investigated as a means to prevent the progression of NAFLD and to promote remission of T2D in these patients. Further studies are warranted to substantiate our findings.
Disclosures
The authors have no commercial associations that might be a conflict of interest in relation to this article.
References (41)
- et al.
Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis
Clin Gastroenterol Hepatol
(2008) - et al.
Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world
Clin Liver Dis
(2016) - et al.
The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: “NASHOST” prospective observational trial
Surg Obes Relat Dis
(2015) - et al.
Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients
Gastroenterol
(2015) - et al.
Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes
Clin Gastroenterol Hepatol
(2015) - et al.
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Gastroenterol
(2012) - et al.
The metabolic syndrome–a new worldwide definition
Lancet
(2005) - et al.
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
Am J Gastroenterol
(1999) Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic
Am J Med Sci
(2011)- et al.
Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery
Surg Obes Relat Dis
(2015)